|
WINNIPEG, Manitoba – February 12th, 2009 – Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, is pleased to announce that Dr. Isabella Caniggia has joined its Scientific Advisory Board. Dr. Caniggia is an internationally recognized preeclampsia researcher and physician at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in Toronto.
Read More
|
|
WINNIPEG, Manitoba – February 10th, 2009 – Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, is pleased to announce results which demonstrate that PSP94 in urine can be used to improve the performance of free over total (F/T) PSA ratio in detecting aggressive prostate cancer. The improvement offered by PSP94 is believed to be a novel discovery.
Read More
|
|
WINNIPEG, Manitoba – January 22, 2009 – Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, announces today the successful completion of testing to characterize the performance of its P2V™ test in an immunoassay format. The results confirmed the test’s diagnostic performance as a biopsy screening tool providing a 91% sensitivity with a 25% specificity. These results are statistically similar in performance to the mass spectrometry assay results which earlier reported the test performing with a 93% sensitivity and a 23% specificity. The P2V™ test is a patent pending combination of two markers, PSP94 and a fragment of vitronectin, for use as a biopsy screen tool for patients with prostate cancer.
Read More
|
|
WINNIPEG, Manitoba – December 31, 2008 - Miraculins Inc. (TSX-V:MOM) (the “Company”), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, has closed its previously announced private placement offering (the "Offering") with aggregate gross proceeds to the Company of $232,500 from the sale of 4,650,000 units ("Units") at a price of $0.05 per Unit. Each Unit is comprised of one common share of the Company (a “Share”) and one Share purchase warrant (a "Warrant"). Each Warrant entitles the holder to purchase one Share at a price of $0.10 per Share for a period of 24 months from the date the Warrant is issued. The net proceeds of the Offering shall be used for research and development and working capital purposes. The Shares and Warrants will be restricted from transfer for a period of four months and a day from the date hereof in accordance with applicable securities laws and the policies of the TSX Venture Exchange.
Read More
|
|
WINNIPEG, Manitoba – December 23, 2008 - Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, announces today an amendment to the terms of its private placement offering (the "Offering") announced on November 10, 2008. The Company is amending the Offering to sell up to 6,000,000 units ("Units") at a price of $0.05 per Unit for gross proceeds of up to $300,000. Each Unit will be comprised of one common share of the Company (a “Share”) and one Share purchase warrant (a "Warrant"). Each Warrant will entitle the holder to purchase one Share at a price of $0.10 per Share for a period of 24 months from the date the Warrant is issued. All other terms of the Offering remain the same.
Read More
|
|
|